Inventor · disambiguated record
Anthony A. Mckinney
Also filed as: MCKINNEY ANTHONY · MCKINNEY ANTHONY A · MCKINNEY ANTHONY ALEXANDER
20 granted patents·52 pending applications·272 citations·filing 2006–2024
95Inventor score
Files withOREXIGEN THERAPEUTICS INC19MCKINNEY ANTHONY ALEXANDER12MCKINNEY ANTHONY7OTSUKA AMERICA PHARMACEUTICAL INC6ETHISMOS RES INC5
Top patents by PatentIndex Score
72 records- 0197US8088786B2Layered pharmaceutical formulationsMCKINNEY ANTHONY·Filed 2007·Granted Jan 3, 2012·64 cites·6 claims
- 0296US9125868B2Methods for administering weight loss medicationsOREXIGEN THERAPEUTICS INC·Filed 2014·Granted Sep 8, 2015·40 cites·17 claims
- 0396US8722085B2Methods for administering weight loss medicationsMCKINNEY ANTHONY·Filed 2010·Granted May 13, 2014·45 cites·17 claims
- 0495US12048769B2Methods for administering weight loss medicationsNALPROPION PHARMACEUTICALS LLC·Filed 2020·Granted Jul 30, 2024·3 cites·20 claims
- 0594US9107837B2Sustained release formulation of naltrexoneOREXIGEN THERAPEUTICS INC·Filed 2014·Granted Aug 18, 2015·13 cites·17 claims
- 0694US8318788B2Layered pharmaceutical formulationsMCKINNEY ANTHONY·Filed 2011·Granted Nov 27, 2012·25 cites·20 claims
- 0792US8916195B2Sustained release formulation of naltrexoneMCKINNEY ANTHONY A·Filed 2007·Granted Dec 23, 2014·23 cites·15 claims
- 0889US10307376B2Methods for administering weight loss medicationsNALPROPION PHARMACEUTICALS INC·Filed 2018·Granted Jun 4, 2019·5 cites·20 claims
- 0989US8815889B2Compositions and methods for increasing insulin sensitivityCOWLEY MICHAEL A·Filed 2006·Granted Aug 26, 2014·18 cites·31 claims
- 1088US9708261B2Crystalline compoundsNEUROVANCE INC·Filed 2016·Granted Jul 18, 2017·6 cites·32 claims
- 1188US9457005B2Compositions and methods for increasing insulin sensitivityOREXIGEN THERAPEUTICS INC·Filed 2014·Granted Oct 4, 2016·9 cites·17 claims
- 1287US10800740B2Crystalline compoundsOTSUKA AMERICA PHARMACEUTICAL INC·Filed 2019·Granted Oct 13, 2020·2 cites·26 claims
- 1386US9856217B2Crystalline compoundsNEUROVANCE INC·Filed 2017·Granted Jan 2, 2018·4 cites·14 claims
- 1486US2024366513A1Methods For Administering Weight Loss MedicationsNALPROPION PHARMACEUTICALS LLC·Filed 2024·Application pending·0 cites
- 1585US11299458B2Crystalline compoundsOTSUKA AMERICA PHARMACEUTICAL INC·Filed 2020·Granted Apr 12, 2022·1 cites·10 claims
- 1684US10280141B2Crystalline compoundsOTSUKA AMERICA PHARMACEUTICAL INC·Filed 2017·Granted May 7, 2019·3 cites·40 claims
- 1784US2023301922A1Layered Pharmaceutical FormulationsNALPROPION PHARMACEUTICALS LLC·Filed 2023·Application pending·0 cites
- 1880US9839627B2Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorderNEUROVANCE INC·Filed 2014·Granted Dec 12, 2017·6 cites·20 claims
- 1980US9566264B2Combinations and methodsEUTHYMICS BIOSCIENCE INC·Filed 2014·Granted Feb 14, 2017·4 cites·23 claims
- 2079US11471438B2MethodsETHISMOS RES INC·Filed 2020·Granted Oct 18, 2022·1 cites·26 claims
- 2177US2024409514A1Methods for inhibiting native and promiscuous uptake of monoamine neurotransmittersETHISMOS RES INC·Filed 2024·Application pending·0 cites
- 2273US2021346469A1Compositions and Methods for Increasing Insulin SensitivityNALPROPION PHARMACEUTICALS LLC·Filed 2021·Application pending·0 cites
- 2373US2021267968A1Compositions And Methods For Reducing Food CravingsNALPROPION PHARMACEUTICALS LLC·Filed 2021·Application pending·0 cites
- 2472US2019183883A1Sustained Release Formulation Of NaltrexoneNALPROPION PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2571US12257233B2MethodsETHISMOS RES INC·Filed 2022·Granted Mar 25, 2025·0 cites·27 claims
- 2670US2014309252A1Compositions and methods for reducing food cravingsOREXIGEN THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 2769US2021046044A1Use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane to treat addictive and alcohol-related disordersMCKINNEY ANTHONY ALEXANDER·Filed 2020·Application pending·0 cites
- 2868US2019282503A1Methods For Administering Weight Loss MedicationsNALPROPION PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2967US2022347157A1Sustained release pharmaceutical compositions comprising (1r, 5s)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexaneOTSUKA AMERICA PHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 3066US2007129283A1Compositions and methods for reducing food cravingsMCKINNEY ANTHONY A·Filed 2006·Application pending·0 cites
- 3165US2021161863A1Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmittersMCKINNEY ANTHONY ALEXANDER·Filed 2020·Application pending·0 cites
- 3265US2015164806A1Layered pharmaceutical formulationsOREXIGEN THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 3365US2008110792A1Methods for administering weight loss medicationsOREXIGEN THERAPEUTICS INC·Filed 2007·Application pending·0 cites
- 3465US2017014404A1Sustained release formulation of naltrexoneOREXIGEN THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3564US2021047268A1Methods for inhibiting native and promiscuous uptake of monoamine neurotransmisttersMCKINNEY ANTHONY·Filed 2020·Application pending·0 cites
- 3663US2016158225A1Sustained release formulation of naltrexoneOREXIGEN THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3763US2019231852A1Compositions And Methods For Increasing Insulin SensitivityNALPROPION PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3862US12042481B2Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmittersOTSUKA AMERICA PHARMACEUTICAL INC·Filed 2021·Granted Jul 23, 2024·0 cites·13 claims
- 3962US2018215710A1Methods for inhibiting native and promiscuous uptake of monoamine neurotransmittersMCKINNEY ANTHONY·Filed 2017·Application pending·0 cites
- 4062US2014228421A1Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine NeurotransmittersMCKINNEY ANTHONY·Filed 2013·Application pending·0 cites
- 4162US2014315892A1Use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane to treat addictive and alcohol-related disordersMCKINNEY ANTHONY ALEXANDER·Filed 2014·Application pending·0 cites
- 4262US2016158221A1Sustained release formulation of naltrexoneOREXIGEN THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 4361US2011028505A1Compositions and methods for reducing food cravingsOREXIGEN THERAPEUTICS INC·Filed 2010·Application pending·0 cites
- 4461US2013177602A1Layered pharmaceutical formulationsOREXIGEN THERAPEUTICS INC·Filed 2012·Application pending·0 cites
- 4561US2018296527A1Use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane to treat addictive and alcohol-related disordersMCKINNEY ANTHONY ALEXANDER·Filed 2017·Application pending·0 cites
- 4661US2022409579A1Methods of treating binge eating disorderOTSUKA AMERICA PHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 4759US2020301415A1Autonomous safety for pedestrians technologyEVEXIA RES LLC·Filed 2019·Application pending·0 cites
- 4859US2016193152A1Methods for administering weight loss medicationsOREXIGEN THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 4958US2016338965A1Layered pharmaceutical formulationsOREXIGEN THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 5058US2017312269A1Compositions and methods for reducing food cravingsOREXIGEN THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Showing the top 50 of 72 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Anthony A. Mckinney files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →